Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:ACAD NASDAQ:MIRM NASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$39.38-1.0%$40.81$16.50▼$48.45$3.67BN/A9,095 shs5,681 shsACADACADIA Pharmaceuticals$21.80+2.0%$24.16$13.40▼$26.65$3.68B0.752.39 million shs1.35 million shsMIRMMirum Pharmaceuticals$72.95+1.7%$68.57$36.88▼$78.10$3.67B0.81732,950 shs490,360 shsMNMDMind Medicine (MindMed)$12.56+2.8%$9.83$4.70▼$12.76$955.69M2.551.70 million shs2.34 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%+5.49%-2.77%-6.33%+3,937,999,900.00%ACADACADIA Pharmaceuticals0.00%+3.56%-13.70%+4.41%+44.37%MIRMMirum Pharmaceuticals0.00%+0.26%-4.09%+44.54%+85.81%MNMDMind Medicine (MindMed)0.00%+17.71%+36.23%+74.44%+125.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$39.38-1.0%$40.81$16.50▼$48.45$3.67BN/A9,095 shs5,681 shsACADACADIA Pharmaceuticals$21.80+2.0%$24.16$13.40▼$26.65$3.68B0.752.39 million shs1.35 million shsMIRMMirum Pharmaceuticals$72.95+1.7%$68.57$36.88▼$78.10$3.67B0.81732,950 shs490,360 shsMNMDMind Medicine (MindMed)$12.56+2.8%$9.83$4.70▼$12.76$955.69M2.551.70 million shs2.34 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%+5.49%-2.77%-6.33%+3,937,999,900.00%ACADACADIA Pharmaceuticals0.00%+3.56%-13.70%+4.41%+44.37%MIRMMirum Pharmaceuticals0.00%+0.26%-4.09%+44.54%+85.81%MNMDMind Medicine (MindMed)0.00%+17.71%+36.23%+74.44%+125.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AACADACADIA Pharmaceuticals 2.62Moderate Buy$29.1233.57% UpsideMIRMMirum Pharmaceuticals 3.00Buy$76.504.87% UpsideMNMDMind Medicine (MindMed) 3.00Buy$26.50110.99% UpsideCurrent Analyst Ratings BreakdownLatest MNMD, MIRM, ACAD, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/29/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$34.00 ➝ $33.009/27/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025MIRMMirum PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MNMDMind Medicine (MindMed)Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025ACADACADIA PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$29.009/25/2025MIRMMirum PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/24/2025MIRMMirum PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/24/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $28.009/24/2025MIRMMirum PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.009/12/2025MIRMMirum PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $77.009/11/2025ACADACADIA PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M27.31N/AN/A$0.48 per share82.04ACADACADIA Pharmaceuticals$957.80M3.84$0.70 per share30.93$4.40 per share4.95MIRMMirum Pharmaceuticals$336.89M10.88N/AN/A$4.70 per share15.52MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AACADACADIA Pharmaceuticals$226.45M$1.3316.3928.687.6821.80%14.69%9.41%11/5/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%11/6/2025 (Estimated)Latest MNMD, MIRM, ACAD, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.38-$0.50-$0.12-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53ACADACADIA PharmaceuticalsN/A2.912.83MIRMMirum Pharmaceuticals1.213.132.97MNMDMind Medicine (MindMed)0.224.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AACADACADIA Pharmaceuticals96.71%MIRMMirum PharmaceuticalsN/AMNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AACADACADIA Pharmaceuticals28.30%MIRMMirum Pharmaceuticals22.87%MNMDMind Medicine (MindMed)2.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.17 millionN/AN/AACADACADIA Pharmaceuticals510168.71 million120.97 millionOptionableMIRMMirum Pharmaceuticals14050.24 million38.75 millionOptionableMNMDMind Medicine (MindMed)4076.09 million74.37 millionOptionableMNMD, MIRM, ACAD, and AAPG HeadlinesRecent News About These CompaniesMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 6.8% - Should You Sell?September 30, 2025 | marketbeat.comMind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) high institutional ownership speaks for itself as stock continues to impress, up 26% over last weekSeptember 30, 2025 | finance.yahoo.comMind Medicine (MindMed) (NASDAQ:MNMD) Hits New 12-Month High - Should You Buy?September 29, 2025 | marketbeat.comDaniel Karlin Sells 7,704 Shares of Mind Medicine (MindMed) (NASDAQ:MNMD) StockSeptember 27, 2025 | insidertrades.comMind Medicine (MindMed) (NASDAQ:MNMD) Insider Sells $75,268.08 in StockSeptember 26, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Insider Sells $110,186.06 in StockSeptember 26, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $252,036.69 in StockSeptember 26, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 7% - Should You Buy?September 23, 2025 | marketbeat.comMindMed Announces New Employee Inducement GrantsSeptember 22, 2025 | businesswire.comGoldman Sachs Group Inc. Has $1.12 Million Position in Mind Medicine (MindMed) Inc. $MNMDSeptember 22, 2025 | marketbeat.comNew MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)September 19, 2025 | financialpost.comFNew MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)September 19, 2025 | businesswire.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of "Buy" from BrokeragesSeptember 17, 2025 | marketbeat.comMindMed Announces New Employee Inducement GrantsSeptember 8, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of ...September 4, 2025 | finance.yahoo.comJournal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)September 4, 2025 | businesswire.comMind Medicine (MindMed) Inc. (MNMD)’s MM120 Earns FDA Breakthrough Status in Anxiety TreatmentSeptember 2, 2025 | finance.yahoo.comMindMed to Participate in September Investor ConferencesAugust 28, 2025 | financialpost.comFMindMed Reports Strong Phase 3 Trial Progress and Leadership AppointmentAugust 25, 2025 | theglobeandmail.comIf You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have TodayAugust 12, 2025 | fool.comCould This Psychedelic Drug Stock Be a Top Buy for 2026?August 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNMD, MIRM, ACAD, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$39.38 -0.40 (-1.01%) As of 10/3/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.ACADIA Pharmaceuticals NASDAQ:ACAD$21.80 +0.42 (+1.96%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$21.78 -0.02 (-0.11%) As of 10/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Mirum Pharmaceuticals NASDAQ:MIRM$72.95 +1.20 (+1.67%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$73.46 +0.51 (+0.70%) As of 10/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Mind Medicine (MindMed) NASDAQ:MNMD$12.56 +0.34 (+2.78%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$12.42 -0.15 (-1.15%) As of 10/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
